Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
June 23rd, 2026 7:45 PM
By: Newsworthy Staff
Quantum BioPharma's novel MS drug candidate Lucid-MS, which directly protects myelin, is progressing to Phase 2 trials after positive Phase 1 safety results, potentially offering a new approach beyond immune modulation.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, toward Phase 2 clinical trials for multiple sclerosis (MS), following successful Phase 1 safety and tolerability studies. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is a patented, first-in-class non-immunomodulatory neuroprotective therapy designed to directly protect the myelin sheath damaged by MS.
According to a BioMedWire editorial highlighting the company's progress, Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies, supported by more than a decade of scientific research. Quantum BioPharma is also collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients, potentially providing a new biomarker for monitoring disease progression and treatment efficacy.
The company's focus on myelin protection represents a paradigm shift in MS therapy, as most existing drugs work by modulating the immune system to reduce inflammation, but do not directly repair or protect the myelin sheath. Lucid-MS aims to fill this gap by targeting the underlying mechanism of MS—myelin degradation—which could offer benefits for patients who do not respond adequately to current treatments.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc. and receives royalty payments of 7% on sales of unbuzzd(TM) until total payments reach $250 million, after which the royalty drops to 3% in perpetuity.
The progression of Lucid-MS to Phase 2 trials is a critical milestone for the company and for MS patients seeking new therapeutic options. For more information, the full press release is available at https://ibn.fm/iZmx1. The latest news and updates relating to QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
